{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T11:20:39Z","timestamp":1793445639431,"version":"4.5.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["DP2OD027590"],"award-info":[{"award-number":["DP2OD027590"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["T32GM007753"],"award-info":[{"award-number":["T32GM007753"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["DP2OD027590"],"award-info":[{"award-number":["DP2OD027590"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Chem Biol"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1038\/s41589-021-00865-9","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T12:02:31Z","timestamp":1637323351000},"page":"1219-1229","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Discovering new biology with drug-resistance alleles"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2953-8133","authenticated-orcid":false,"given":"Allyson M.","family":"Freedy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2985-462X","authenticated-orcid":false,"given":"Brian B.","family":"Liau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,19]]},"reference":[{"key":"865_CR1","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/clinids\/1.3.434","volume":"1","author":"A Tomasz","year":"1979","unstructured":"Tomasz, A. From penicillin-binding proteins to the lysis and death of bacteria: a 1979 view. Rev. Infect. Dis. 1, 434\u2013467 (1979).","journal-title":"Rev. Infect. Dis."},{"key":"865_CR2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1083\/jcb.34.2.525","volume":"34","author":"GG Borisy","year":"1967","unstructured":"Borisy, G. G. & Taylor, E. W. The mechanism of action of colchicine. Binding of colchincine-3H to cellular protein. J. Cell Biol. 34, 525\u2013533 (1967).","journal-title":"J. Cell Biol."},{"key":"865_CR3","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon, S. J. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060\u20131072 (2012).","journal-title":"Cell"},{"key":"865_CR4","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nchembio.1199","volume":"9","author":"M Schenone","year":"2013","unstructured":"Schenone, M., Dan\u010d\u00edk, V., Wagner, B. K. & Clemons, P. A. Target identification and mechanism of action in chemical biology and drug discovery. Nat. Chem. Biol. 9, 232\u2013240 (2013).","journal-title":"Nat. Chem. Biol."},{"key":"865_CR5","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.1247005","volume":"343","author":"O Shalem","year":"2014","unstructured":"Shalem, O. et al. Genome-scale CRISPR\u2013Cas9 knockout screening in human cells. Science 343, 84\u201387 (2014).","journal-title":"Science"},{"key":"865_CR6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1126\/science.1246981","volume":"343","author":"T Wang","year":"2014","unstructured":"Wang, T., Wei, J. J., Sabatini, D. M. & Lander, E. S. Genetic screens in human cells using the CRISPR\u2013Cas9 system. Science 343, 80\u201384 (2014).","journal-title":"Science"},{"key":"865_CR7","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/220275a0","volume":"220","author":"GP Tochini-Valentini","year":"1968","unstructured":"Tochini-Valentini, G. P., Marino, P. & Colvill, A. J. Mutant of E. coli containing an altered DNA-dependent RNA polymerase. Nature 220, 275\u2013276 (1968).","journal-title":"Nature"},{"key":"865_CR8","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/220276a0","volume":"220","author":"DH Ezekial","year":"1968","unstructured":"Ezekial, D. H. & Hutchins, J. E. Mutations affecting RNA polymerase associated with rifampicin resistance in Escherichia coli. Nature 220, 276\u2013277 (1968).","journal-title":"Nature"},{"key":"865_CR9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/222333a0","volume":"222","author":"M Ozaki","year":"1969","unstructured":"Ozaki, M., Mizushima, S. & Nomura, M. Identification and functional characterization of the protein controlled by the streptomycin-resistant locus in E. coli. Nature 222, 333\u2013339 (1969).","journal-title":"Nature"},{"key":"865_CR10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/254161a0","volume":"254","author":"EW Branscomb","year":"1975","unstructured":"Branscomb, E. W. & Galas, D. J. Progressive decrease in protein synthesis accuracy induced by streptomycin in Escherichia coli. Nature 254, 161\u2013163 (1975).","journal-title":"Nature"},{"key":"865_CR11","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/262617b0","volume":"262","author":"DJ Galas","year":"1976","unstructured":"Galas, D. J. & Branscomb, E. W. Ribosome slowed by mutation to streptomycin resistance. Nature 262, 617\u2013619 (1976). This study showed that streptomycin resistance mutations, which were known to increase the accuracy of translation, also led to decreased translational kinetics. This finding demonstrated that the accuracy of translation was in part dictated by the speed of translation.","journal-title":"Nature"},{"key":"865_CR12","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1073\/pnas.43.5.416","volume":"43","author":"FHC Crick","year":"1957","unstructured":"Crick, F. H. C., Griffith, J. S. & Orgel, L. E. Codes without commas. Proc. Natl Acad. Sci. USA 43, 416\u2013421 (1957).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"865_CR13","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1126\/science.1715094","volume":"253","author":"J Heitman","year":"1991","unstructured":"Heitman, J., Movva, N. R. & Hall, M. N. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253, 905\u2013909 (1991). This paper reported the first identification of a TOR gene in any organism.","journal-title":"Science"},{"key":"865_CR14","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/341758a0","volume":"341","author":"MW Harding","year":"1989","unstructured":"Harding, M. W., Galat, A., Uehlingt, D. E. & Schreibert, S. L. A receptor for the immuno-suppressant FK506 is a cis\u2013trans peptidyl-prolyl isomerase. Nature 341, 758\u2013760 (1989).","journal-title":"Nature"},{"key":"865_CR15","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/369756a0","volume":"369","author":"EJ Brown","year":"1994","unstructured":"Brown, E. J. et al. A mammalian protein targeted by G1-arresting rapamycin\u2013receptor complex. Nature 369, 756\u2013758 (1994).","journal-title":"Nature"},{"key":"865_CR16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/0092-8674(94)90570-3","volume":"78","author":"DM Sabatini","year":"1994","unstructured":"Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P. & Snyder, S. H. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78, 35\u201343 (1994).","journal-title":"Cell"},{"key":"865_CR17","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1074\/jbc.270.2.815","volume":"270","author":"CJ Sabers","year":"1995","unstructured":"Sabers, C. J. et al. Isolation of a protein target of the FKBP12\u2013rapamycin complex in mammalian cells. J. Biol. Chem. 270, 815\u2013822 (1995).","journal-title":"J. Biol. Chem."},{"key":"865_CR18","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/0092-8674(91)90124-H","volume":"66","author":"J Liu","year":"1991","unstructured":"Liu, J. et al. Calcineurin is a common target of cyclophilin\u2013cyclosporin A and FKBP\u2013FK506 complexes. Cell 66, 807\u2013815 (1991).","journal-title":"Cell"},{"key":"865_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.cell.2020.12.020","volume":"184","author":"SL Schreiber","year":"2021","unstructured":"Schreiber, S. L. The rise of molecular glues. Cell 184, 3\u20139 (2021).","journal-title":"Cell"},{"key":"865_CR20","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nchembio.1551","volume":"10","author":"C Kasap","year":"2014","unstructured":"Kasap, C., Elemento, O. & Kapoor, T. M. DrugTargetSeqR: a genomics- and CRISPR\u2013Cas9-based method to analyze drug targets. Nat. Chem. Biol. 10, 626\u2013628 (2014).","journal-title":"Nat. Chem. Biol."},{"key":"865_CR21","doi-asserted-by":"publisher","first-page":"eaal3755","DOI":"10.1126\/science.aal3755","volume":"356","author":"T Han","year":"2017","unstructured":"Han, T. et al. Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15. Science 356, eaal3755 (2017).","journal-title":"Science"},{"key":"865_CR22","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/nchembio.2363","volume":"13","author":"T Uehara","year":"2017","unstructured":"Uehara, T. et al. Selective degradation of splicing factor CAPER\u03b1 by anticancer sulfonamides. Nat. Chem. Biol. 13, 675\u2013680 (2017).","journal-title":"Nat. Chem. Biol."},{"key":"865_CR23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/0014-5793(89)81531-5","volume":"259","author":"M Noda","year":"1989","unstructured":"Noda, M., Suzuki, H., Numa, S. & Stiihmer, W. A single point mutation confers tetrodotoxin and saxitoxin insensitivity on the sodium channel II. FEBS Lett. 259, 213\u2013216 (1989).","journal-title":"FEBS Lett."},{"key":"865_CR24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/0014-5793(91)81159-6","volume":"293","author":"H Terlau","year":"1991","unstructured":"Terlau, H. et al. Mapping the site of block by tetrodotoxin and saxitoxin of sodium channel H. FEBS Lett. 293, 93\u201396 (1991).","journal-title":"FEBS Lett."},{"key":"865_CR25","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/356441a0","volume":"356","author":"SH Heinemann","year":"1992","unstructured":"Heinemann, S. H., Terlau, H., Stuhmer, W., Imoto, K. & Numa, S. Calcium channel characteristics conferred on the sodium channel by single mutations. Nature 356, 441\u2013443 (1992).","journal-title":"Nature"},{"key":"865_CR26","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/374660a0","volume":"374","author":"H Gerber","year":"1995","unstructured":"Gerber, H. et al. RNA polymerase II C-terminal domain required for enhancer-driven transcription. Nature 374, 660\u2013662 (1995).","journal-title":"Nature"},{"key":"865_CR27","first-page":"330","volume":"8","author":"MS Bartolomei","year":"1988","unstructured":"Bartolomei, M. S., Halden, N. F., Cullen, C. R. & Corden, J. L. Genetic analysis of the repetitive carboxyl-terminal domain of the largest subunit of mouse RNA polymerase II. Mol. Cell. Biol. 8, 330\u2013339 (1988).","journal-title":"Mol. Cell. Biol."},{"key":"865_CR28","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0092-8674(03)00190-9","volume":"112","author":"M Azam","year":"2003","unstructured":"Azam, M., Latek, R. R. & Daley, G. Q. Mechanisms of autoinhibition and STI-571\/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112, 831\u2013843 (2003). This report identified a novel mechanism of autoinhibition for ABL kinase through characterization of imatinib resistance mutations outside of the drug-binding site.","journal-title":"Cell"},{"key":"865_CR29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/00062752-200401000-00006","volume":"11","author":"V Nardi","year":"2004","unstructured":"Nardi, V., Azam, M. & Daley, G. Q. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr. Opin. Hematol. 11, 35\u201343 (2004).","journal-title":"Curr. Opin. Hematol."},{"key":"865_CR30","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0092-8674(03)00194-6","volume":"112","author":"B Nagar","year":"2003","unstructured":"Nagar, B. et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112, 859\u2013871 (2003).","journal-title":"Cell"},{"key":"865_CR31","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S0092-8674(03)00191-0","volume":"112","author":"O Hantschel","year":"2003","unstructured":"Hantschel, O. et al. A myristoyl\/phosphotyrosine switch regulates c-Abl. Cell 112, 845\u2013857 (2003).","journal-title":"Cell"},{"key":"865_CR32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nchembio760","volume":"2","author":"FJ Adri\u00e1n","year":"2006","unstructured":"Adri\u00e1n, F. J. et al. Allosteric inhibitors of Bcr-Abl-dependent cell proliferation. Nat. Chem. Biol. 2, 95\u2013102 (2006).","journal-title":"Nat. Chem. Biol."},{"key":"865_CR33","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nature21702","volume":"543","author":"AA Wylie","year":"2017","unstructured":"Wylie, A. A. et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature 543, 733\u2013737 (2017).","journal-title":"Nature"},{"key":"865_CR34","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1093\/nar\/gku511","volume":"42","author":"A Melnikov","year":"2014","unstructured":"Melnikov, A., Rogov, P., Wang, L., Gnirke, A. & Mikkelsen, T. S. Comprehensive mutational scanning of a kinase in vivo reveals substrate-dependent fitness landscapes. Nucleic Acids Res. 42, e112 (2014).","journal-title":"Nucleic Acids Res."},{"key":"865_CR35","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41594-019-0358-z","volume":"27","author":"NS Persky","year":"2020","unstructured":"Persky, N. S. et al. Defining the landscape of ATP-competitive inhibitor resistance residues in protein kinases. Nat. Struct. Mol. Biol. 27, 92\u2013104 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"865_CR36","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/44579","volume":"401","author":"U Rudolph","year":"1999","unstructured":"Rudolph, U. et al. Benzodiazepine actions mediated by specific \u03b3-aminobutyric acidA receptor subtypes. Nature 401, 796\u2013800 (1999). Using mouse models with resistance mutations in specific GABA receptor subtypes, this report identified the specific GABA receptor subtypes and thus brain regions that mediated different aspects of the physiological response to benzodiazepines.","journal-title":"Nature"},{"key":"865_CR37","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/75761","volume":"3","author":"RM McKernan","year":"2000","unstructured":"McKernan, R. M. et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor \u03b11 subtype. Nat. Neurosci. 3, 587\u2013592 (2000).","journal-title":"Nat. Neurosci."},{"key":"865_CR38","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1126\/science.290.5489.131","volume":"290","author":"K Low","year":"2000","unstructured":"Low, K. et al. Molecular and neuronal substrate for the selective attenuation of anxiety. Science 290, 131\u2013134 (2000).","journal-title":"Science"},{"key":"865_CR39","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/s41401-018-0185-5","volume":"40","author":"X Chen","year":"2019","unstructured":"Chen, X., Gerven, J., van, Cohen, A. & Jacobs, G. Human pharmacology of positive GABA-A subtype-selective receptor modulators for the treatment of anxiety. Acta Pharm. Sin. 40, 571\u2013582 (2019).","journal-title":"Acta Pharm. Sin."},{"key":"865_CR40","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","volume":"359","author":"S Mallal","year":"2002","unstructured":"Mallal, S. et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359, 727\u2013732 (2002).","journal-title":"Lancet"},{"key":"865_CR41","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/nature11147","volume":"486","author":"PT Illing","year":"2012","unstructured":"Illing, P. T. et al. Immune self-reactivity triggered by drug-modified HLA\u2013peptide repertoire. Nature 486, 554\u2013558 (2012).","journal-title":"Nature"},{"key":"865_CR42","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/S0140-6736(61)90927-8","volume":"278","author":"WG Mcbride","year":"1961","unstructured":"Mcbride, W. G. Thalidomide and congenital abnormalities. Lancet 278, 1358 (1961).","journal-title":"Lancet"},{"key":"865_CR43","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1126\/science.1177319","volume":"327","author":"T Ito","year":"2010","unstructured":"Ito, T. et al. Identification of a primary target of thalidomide teratogenicity. Science 327, 1345\u20131350 (2010). This study identified CRBN as the target of thalidomide. CRBN resistance mutations were used to show that thalidomide binding to CRBN was necessary for thalidomide\u2019s teratogenicity in zebrafish.","journal-title":"Science"},{"key":"865_CR44","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41594-020-0438-0","volume":"27","author":"T Wu","year":"2020","unstructured":"Wu, T. et al. Targeted protein degradation as a powerful research tool in basic biology and drug target discovery. Nat. Struct. Mol. Biol. 27, 605\u2013614 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"865_CR45","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/0041-008X(65)90095-5","volume":"7","author":"ID Fratta","year":"1965","unstructured":"Fratta, I. D., Sigg, E. B., Maiorana, K. & Davies, S. Teratogenic effects of thalidomide in rabbits, rats, hamsters and mice. Toxicol. Appl. Pharmacol. 7, 268\u2013286 (1965).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"865_CR46","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nature14610","volume":"523","author":"J Kr\u00f6nke","year":"2015","unstructured":"Kr\u00f6nke, J. et al. Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del(5q) MDS. Nature 523, 183\u2013188 (2015). This paper identified the genetic variation in CRBN responsible for the difference in the antineoplastic activity of thalidomide and its analogs between mice and humans.","journal-title":"Nature"},{"key":"865_CR47","doi-asserted-by":"publisher","first-page":"e38430","DOI":"10.7554\/eLife.38430","volume":"7","author":"KA Donovan","year":"2018","unstructured":"Donovan, K. A. et al. Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane radial ray syndrome. eLife 7, e38430 (2018).","journal-title":"eLife"},{"key":"865_CR48","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41594-020-0405-9","volume":"27","author":"ME Matyskiela","year":"2020","unstructured":"Matyskiela, M. E. et al. Crystal structure of the SALL4\u2013pomalidomide\u2013cereblon\u2013DDB1 complex. Nat. Struct. Mol. Biol. 27, 319\u2013322 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"865_CR49","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1182\/blood-2018-05-852798","volume":"132","author":"EC Fink","year":"2018","unstructured":"Fink, E. C. et al. CrbnI391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice. Blood 132, 1535\u20131544 (2018).","journal-title":"Blood"},{"key":"865_CR50","first-page":"473","volume":"40","author":"J Kohlhase","year":"2003","unstructured":"Kohlhase, J. et al. Mutations at the SALL4 locus on chromosome 20 result in a range of clinically overlapping phenotypes, including Okihiro syndrome, Holt\u2013Oram syndrome, acro-renal-ocular syndrome, and patients previously reported to represent thalidomide embryopathy. Hum. Mol. Genet. 40, 473\u2013478 (2003).","journal-title":"Hum. Mol. Genet."},{"key":"865_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5840\/jpsl20111133","volume":"11","author":"R Greek","year":"2011","unstructured":"Greek, R., Shanks, N. & Rice, M. J. The history and implications of testing thalidomide on animals. J. Philos. Sci. Law 11, 1\u201332 (2011).","journal-title":"J. Philos. Sci. Law"},{"key":"865_CR52","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1073\/pnas.0711741105","volume":"105","author":"J Tsai","year":"2008","unstructured":"Tsai, J. et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl Acad. Sci. USA 105, 3041\u20133046 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"865_CR53","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/nature09454","volume":"467","author":"G Bollag","year":"2010","unstructured":"Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596\u2013599 (2010).","journal-title":"Nature"},{"key":"865_CR54","doi-asserted-by":"publisher","first-page":"9033","DOI":"10.1200\/jco.2008.26.15_suppl.9033","volume":"26","author":"R Dummer","year":"2008","unstructured":"Dummer, R. et al. AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: an open-label, randomized, multicenter, phase II study. J. Clin. Oncol. 26, 9033 (2008).","journal-title":"J. Clin. Oncol."},{"key":"865_CR55","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nrc.2017.79","volume":"17","author":"Z Karoulia","year":"2017","unstructured":"Karoulia, Z., Gavathiotis, E. & Poulikakos, P. I. New perspectives for targeting RAF kinase in human cancer. Nat. Rev. Cancer 17, 676\u2013691 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"865_CR56","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nature08902","volume":"464","author":"PI Poulikakos","year":"2010","unstructured":"Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M. & Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427\u2013430 (2010). This study used allele-selective kinase inhibitors to identify the mechanism underlying paradoxical activation by canonical BRAF inhibitors such as vemurafenib.","journal-title":"Nature"},{"key":"865_CR57","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature08833","volume":"464","author":"G Hatzivassiliou","year":"2010","unstructured":"Hatzivassiliou, G. et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431\u2013435 (2010).","journal-title":"Nature"},{"key":"865_CR58","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1021\/ja983267v","volume":"121","author":"AC Bishop","year":"1999","unstructured":"Bishop, A. C. et al. Generation of monospecific nanomolar tyrosine kinase inhibitors via a chemical genetic approach. J. Am. Chem. Soc. 121, 627\u2013631 (1999).","journal-title":"J. Am. Chem. Soc."},{"key":"865_CR59","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/35050080","volume":"408","author":"AC Bishop","year":"2000","unstructured":"Bishop, A. C. et al. A chemical switch for inhibitor-sensitive alleles. Nature 408, 961\u2013964 (2000).","journal-title":"Nature"},{"key":"865_CR60","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/nchembio866","volume":"3","author":"JA Blair","year":"2007","unstructured":"Blair, J. A. et al. Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat. Chem. Biol. 3, 229\u2013238 (2007).","journal-title":"Nat. Chem. Biol."},{"key":"865_CR61","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.chembiol.2018.07.001","volume":"25","author":"K Islam","year":"2018","unstructured":"Islam, K. The bump-and-hole tactic: expanding the scope of chemical genetics. Cell Chem. Biol. 25, 1171\u20131184 (2018). This review provides an excellent overview of bump\u2013hole techniques and their applications across a variety of fields.","journal-title":"Cell Chem. Biol."},{"key":"865_CR62","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nature08314","volume":"461","author":"T Rajakulendran","year":"2009","unstructured":"Rajakulendran, T., Sahmi, M., Lefran\u00e7ois, M., Sicheri, F. & Therrien, M. A dimerization-dependent mechanism drives RAF catalytic activation. Nature 461, 542\u2013545 (2009).","journal-title":"Nature"},{"key":"865_CR63","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ccell.2016.06.024","volume":"30","author":"Z Karoulia","year":"2016","unstructured":"Karoulia, Z. et al. An integrated model of RAF inhibitor action predicts inhibitor activity against oncogenic BRAF signaling. Cancer Cell 30, 485\u2013498 (2016).","journal-title":"Cancer Cell"},{"key":"865_CR64","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1126\/science.aay0543","volume":"366","author":"Y Kondo","year":"2019","unstructured":"Kondo, Y. et al. Cryo-EM structure of a dimeric B-Raf:14-3-3 complex reveals asymmetry in the active sites of B-Raf kinases. Science 366, 109\u2013115 (2019).","journal-title":"Science"},{"key":"865_CR65","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nature10662","volume":"480","author":"PI Poulikakos","year":"2011","unstructured":"Poulikakos, P. I. et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAFV600E. Nature 480, 387\u2013390 (2011). This study identified and characterized the BRAF p61 isoform as resistant to canonical BRAF inhibitors such as vemurafenib. The BRAF p61 isoform both confirmed the mechanism of action of first-generation BRAF inhibitors such as vemurafenib and was used as a tool in later studies to identify next-generation therapeutic candidates targeting the MAPK pathway.","journal-title":"Nature"},{"key":"865_CR66","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/2159-8290.CD-11-0341","volume":"2","author":"RB Corcoran","year":"2012","unstructured":"Corcoran, R. B. et al. EGFR-mediated reactivation of MAPK signaling contributes to insensitivity of BRAF-mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2, 227\u2013235 (2012).","journal-title":"Cancer Discov."},{"key":"865_CR67","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.1038\/s41467-020-18123-2","volume":"11","author":"XM Cotto-Rios","year":"2020","unstructured":"Cotto-Rios, X. M. et al. Inhibitors of BRAF dimers using an allosteric site. Nat. Commun. 11, 4370 (2020).","journal-title":"Nat. Commun."},{"key":"865_CR68","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1158\/2159-8290.CD-20-1351","volume":"11","author":"C Adamopoulos","year":"2021","unstructured":"Adamopoulos, C. et al. Exploiting allosteric properties of RAF and MEK inhibitors to target therapy-resistant tumors driven by oncogenic BRAF signaling. Cancer Discov. 11, 1716\u20131735 (2021).","journal-title":"Cancer Discov."},{"key":"865_CR69","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41589-019-0263-0","volume":"15","author":"M Vinyard","year":"2019","unstructured":"Vinyard, M. et al. CRISPR-suppressor scanning reveals a nonenzymatic role of LSD1 in AML. Nat. Chem. Biol. 15, 529\u2013539 (2019).","journal-title":"Nat. Chem. Biol."},{"key":"865_CR70","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1016\/j.celrep.2018.03.012","volume":"22","author":"A Maiques-Diaz","year":"2018","unstructured":"Maiques-Diaz, A. et al. Enhancer activation by pharmacologic displacement of LSD1 from GFI1 induces differentiation in acute myeloid leukemia. Cell Rep. 22, 3641\u20133659 (2018).","journal-title":"Cell Rep."},{"key":"865_CR71","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.cell.2013.07.030","volume":"154","author":"NT Hertz","year":"2013","unstructured":"Hertz, N. T. et al. A neo-substrate that amplifies catalytic activity of Parkinson\u2019s-disease- related kinase PINK1. Cell 154, 737\u2013747 (2013).","journal-title":"Cell"},{"key":"865_CR72","doi-asserted-by":"publisher","first-page":"6524","DOI":"10.1038\/s41598-019-43005-z","volume":"9","author":"JL Suh","year":"2019","unstructured":"Suh, J. L. et al. Discovery of selective activators of PRC2 mutant EED-I363M. Sci. Rep. 9, 6524 (2019).","journal-title":"Sci. Rep."},{"key":"865_CR73","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-020-2374-x","volume":"585","author":"M S\u0142abicki","year":"2020","unstructured":"S\u0142abicki, M. et al. The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K. Nature 585, 293\u2013297 (2020).","journal-title":"Nature"},{"key":"865_CR74","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/s41586-020-2925-1","volume":"588","author":"M S\u0142abicki","year":"2020","unstructured":"S\u0142abicki, M. et al. Small-molecule-induced polymerization triggers degradation of BCL6. Nature 588, 164\u2013168 (2020).","journal-title":"Nature"},{"key":"865_CR75","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1038\/nprot.2012.069","volume":"7","author":"R Hietpas","year":"2012","unstructured":"Hietpas, R., Roscoe, B., Jiang, L. & Bolon, D. N. A. Fitness analyses of all possible point mutations for regions of genes in yeast. Nat. Protoc. 7, 1382\u20131396 (2012).","journal-title":"Nat. Protoc."},{"key":"865_CR76","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.celrep.2013.01.019","volume":"3","author":"Z Huang","year":"2013","unstructured":"Huang, Z. et al. A functional variomics tool for discovering drug-resistance genes and drug targets. Cell Rep. 3, 577\u2013585 (2013).","journal-title":"Cell Rep."},{"key":"865_CR77","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.celrep.2015.03.040","volume":"11","author":"TJ Wu","year":"2015","unstructured":"Wu, T. J. et al. Identification of a non-Gatekeeper hot spot for drug-resistant mutations in mTOR kinase. Cell Rep. 11, 446\u2013459 (2015).","journal-title":"Cell Rep."},{"key":"865_CR78","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/j.celrep.2019.09.079","volume":"29","author":"TC Ting","year":"2019","unstructured":"Ting, T. C. et al. Aryl sulfonamides degrade RBM39 and RBM23 by recruitment to CRL4\u2013DCAF15. Cell Rep. 29, 1499\u20131510 (2019).","journal-title":"Cell Rep."},{"key":"865_CR79","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.celrep.2016.09.061","volume":"17","author":"L Brenan","year":"2016","unstructured":"Brenan, L. et al. Phenotypic characterization of a comprehensive set of MAPK1\/ERK2 missense mutants. Cell Rep. 17, 1171\u20131183 (2016).","journal-title":"Cell Rep."},{"key":"865_CR80","doi-asserted-by":"publisher","first-page":"eaat0572","DOI":"10.1126\/science.aat0572","volume":"362","author":"QL Sievers","year":"2018","unstructured":"Sievers, Q. L. et al. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Science 362, eaat0572 (2018).","journal-title":"Science"},{"key":"865_CR81","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41588-018-0204-y","volume":"50","author":"AO Giacomelli","year":"2018","unstructured":"Giacomelli, A. O. et al. Mutational processes shape the landscape of TP53 mutations in human cancer. Nat. Genet. 50, 1381\u20131387 (2018).","journal-title":"Nat. Genet."},{"key":"865_CR82","doi-asserted-by":"publisher","first-page":"e0170445","DOI":"10.1371\/journal.pone.0170445","volume":"12","author":"KF Donovan","year":"2017","unstructured":"Donovan, K. F. et al. Creation of novel protein variants with CRISPR\/Cas9-mediated mutagenesis: turning a screening by-product into a discovery tool. PLoS ONE 12, e0170445 (2017).","journal-title":"PLoS ONE"},{"key":"865_CR83","doi-asserted-by":"publisher","first-page":"e0172177","DOI":"10.1371\/journal.pone.0172177","volume":"12","author":"JJ Ipsaro","year":"2017","unstructured":"Ipsaro, J. J. et al. Rapid generation of drug-resistance alleles at endogenous loci using CRISPR\u2013Cas9 indel mutagenesis. PLoS ONE 12, e0172177 (2017).","journal-title":"PLoS ONE"},{"key":"865_CR84","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/s41467-017-02349-8","volume":"9","author":"JE Neggers","year":"2018","unstructured":"Neggers, J. E. et al. Target identification of small molecules using large-scale CRISPR\u2013Cas mutagenesis scanning of essential genes. Nat. Commun. 9, 502 (2018).","journal-title":"Nat. Commun."},{"key":"865_CR85","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/nature13695","volume":"513","author":"GM Findlay","year":"2014","unstructured":"Findlay, G. M., Boyle, E. A., Hause, R. J., Klein, J. C. & Shendure, J. Saturation editing of genomic regions by multiplex homology-directed repair. Nature 513, 120\u2013123 (2014).","journal-title":"Nature"},{"key":"865_CR86","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1126\/science.aar5129","volume":"359","author":"AF Zyryanova","year":"2018","unstructured":"Zyryanova, A. F. et al. Binding of ISRIB reveals a regulatory site in the nucleotide exchange factor eIF2B. Science 359, 1533\u20131536 (2018).","journal-title":"Science"},{"key":"865_CR87","doi-asserted-by":"publisher","first-page":"11751","DOI":"10.1073\/pnas.1708268114","volume":"114","author":"L Ma","year":"2017","unstructured":"Ma, L. et al. CRISPR\u2013Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy. Proc. Natl Acad. Sci. USA 114, 11751\u201311756 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"865_CR88","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nature17946","volume":"533","author":"AC Komor","year":"2016","unstructured":"Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533, 420\u2013424 (2016).","journal-title":"Nature"},{"key":"865_CR89","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nature24644","volume":"551","author":"NM Gaudelli","year":"2017","unstructured":"Gaudelli, N. M. et al. Programmable base editing of A\u2022T to G\u2022C in genomic DNA without DNA cleavage. Nature 551, 464\u2013471 (2017).","journal-title":"Nature"},{"key":"865_CR90","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1038\/nmeth.4027","volume":"13","author":"Y Ma","year":"2016","unstructured":"Ma, Y. et al. Targeted AID-mediated mutagenesis (TAM) enables efficient genomic diversification in mammalian cells. Nat. Methods 13, 1029\u20131035 (2016).","journal-title":"Nat. Methods"},{"key":"865_CR91","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/nmeth.4038","volume":"13","author":"GT Hess","year":"2016","unstructured":"Hess, G. T. et al. Directed evolution using dCas9-targeted somatic hypermutation in mammalian cells. Nat. Methods 13, 1036\u20131042 (2016).","journal-title":"Nat. Methods"},{"key":"865_CR92","doi-asserted-by":"publisher","first-page":"11560","DOI":"10.1021\/jacs.8b04001","volume":"140","author":"CL Moore","year":"2018","unstructured":"Moore, C. L., Papa, L. J. & Shoulders, M. D. A processive protein chimera introduces mutations across defined DNA regions in vivo. J. Am. Chem. Soc. 140, 11560\u201311564 (2018).","journal-title":"J. Am. Chem. Soc."},{"key":"865_CR93","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41587-019-0331-8","volume":"38","author":"H Chen","year":"2020","unstructured":"Chen, H. et al. Efficient, continuous mutagenesis in human cells using a pseudo-random DNA editor. Nat. Biotechnol. 38, 165\u2013168 (2020).","journal-title":"Nat. Biotechnol."},{"key":"865_CR94","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.cell.2021.01.012","volume":"184","author":"RE Hanna","year":"2021","unstructured":"Hanna, R. E. et al. Massively parallel assessment of human variants with base editor screens. Cell 184, 1064\u20131080 (2021).","journal-title":"Cell"},{"key":"865_CR95","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.cell.2021.01.041","volume":"184","author":"R Cuella-Martin","year":"2021","unstructured":"Cuella-Martin, R. et al. Functional interrogation of DNA damage response variants with base editing screens. Cell 184, 1081\u20131097 (2021).","journal-title":"Cell"},{"key":"865_CR96","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","volume":"576","author":"AV Anzalone","year":"2019","unstructured":"Anzalone, A. V. et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, 149\u2013157 (2019).","journal-title":"Nature"},{"key":"865_CR97","doi-asserted-by":"publisher","unstructured":"Erwood, S. et al. Saturation variant interpretation using CRISPR prime editing. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2021.05.11.443710 (2021).","DOI":"10.1101\/2021.05.11.443710"},{"key":"865_CR98","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s41589-019-0225-6","volume":"15","author":"T Cupido","year":"2019","unstructured":"Cupido, T., Pisa, R., Kelley, M. E. & Kapoor, T. M. Designing a chemical inhibitor for the AAA protein spastin using active site mutations. Nat. Chem. Biol. 15, 444\u2013452 (2019). This report demonstrated the successful use of RADD to develop a selective inhibitor of the AAA protein spastin.","journal-title":"Nat. Chem. Biol."},{"key":"865_CR99","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.chembiol.2019.06.001","volume":"26","author":"R Pisa","year":"2019","unstructured":"Pisa, R., Cupido, T., Steinman, J. B., Jones, N. H. & Kapoor, T. M. Analyzing resistance to design selective chemical inhibitors for AAA proteins. Cell Chem. Biol. 26, 1263\u20131273 (2019).","journal-title":"Cell Chem. Biol."}],"container-title":["Nature Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41589-021-00865-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41589-021-00865-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41589-021-00865-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T22:08:20Z","timestamp":1675721300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41589-021-00865-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,19]]},"references-count":99,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["865"],"URL":"https:\/\/doi.org\/10.1038\/s41589-021-00865-9","relation":{},"ISSN":["1552-4450","1552-4469"],"issn-type":[{"value":"1552-4450","type":"print"},{"value":"1552-4469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,19]]},"assertion":[{"value":"26 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}